Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Galderma Q3 Sales Climb; Confirms FY26 Core EBITDA Margin View, Lifts Sales Growth Outlook; Stock Up

(RTTNews) - Galderma Group AG (GALD.SW, GALDY), a Swiss pharmaceutical company, reported Thursday strong growth in third-quarter sales, with broad-based double-digit growth across geographies and product categories.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

More from Thursday 22 October →